- Home
- DMAC vs ACCO Comparison
DMAC vs ACCO Comparison
Compare DMAC & ACCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- ACCO
- Stock Information
- Founded
- DMAC 2000
- ACCO 1893
- Country
- DMAC United States
- ACCO United States
- Employees
- DMAC N/A
- ACCO N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- ACCO Publishing
- Sector
- DMAC Health Care
- ACCO Consumer Discretionary
- Exchange
- DMAC Nasdaq
- ACCO Nasdaq
- Market Cap
- DMAC 321.5M
- ACCO 356.9M
- IPO Year
- DMAC N/A
- ACCO N/A
- Fundamental
- Price
- DMAC $5.95
- ACCO $3.43
- Analyst Decision
- DMAC Strong Buy
- ACCO Buy
- Analyst Count
- DMAC 4
- ACCO 1
- Target Price
- DMAC $15.50
- ACCO $6.00
- AVG Volume (30 Days)
- DMAC 315.3K
- ACCO 657.2K
- Earning Date
- DMAC 11-12-2025
- ACCO 10-30-2025
- Dividend Yield
- DMAC N/A
- ACCO 8.77%
- EPS Growth
- DMAC N/A
- ACCO N/A
- EPS
- DMAC N/A
- ACCO 0.43
- Revenue
- DMAC N/A
- ACCO $1,544,000,000.00
- Revenue This Year
- DMAC N/A
- ACCO N/A
- Revenue Next Year
- DMAC N/A
- ACCO $2.11
- P/E Ratio
- DMAC N/A
- ACCO $7.92
- Revenue Growth
- DMAC N/A
- ACCO N/A
- 52 Week Low
- DMAC $3.19
- ACCO $3.32
- 52 Week High
- DMAC $7.49
- ACCO $6.32
- Technical
- Relative Strength Index (RSI)
- DMAC 42.03
- ACCO 31.69
- Support Level
- DMAC $5.26
- ACCO $3.41
- Resistance Level
- DMAC $6.47
- ACCO $3.56
- Average True Range (ATR)
- DMAC 0.41
- ACCO 0.14
- MACD
- DMAC -0.10
- ACCO -0.03
- Stochastic Oscillator
- DMAC 36.50
- ACCO 2.21
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About ACCO Acco Brands Corporation
ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.